Coronary heart disease The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction

Aims Multiple studies have focused on the relationship of body anthropometric measures with clinical events in ST-elevation myocardial infarction (STEMI) patients, highlighting the ‘obesity paradox’. However, the relative prognostic importance of these measures over other baseline variables is less known. Method and results We performed a retrospective analysis of 94 108 STEMI patients from seven clinical trials evaluating various reperfusion strategies to study the relationship and prognostic importance of height, weight, body mass index (BMI), and body surface area (BSA) with 30-day death and in-hospital cardiogenic shock, major bleeding, and stroke. Main outcome measures of interest included 30-day death and in-hospital cardiogenic shock, major bleeding, and stroke. Weight, BMI, and BSA were inversely and independently related to all clinical events. Despite being statistically significant (P, 0.0001), the prognostic information contributed by weight beyond that conferred by baseline clinical factors was minimal (,1% of total prognostic information) making it of limited clinical relevance for predicting 30-day death and cardiogenic shock. In contrast, weight accounted for 8.4% and 4.3% of the prognostic information in the logistic regression models for major bleeding and for stroke. BMI or BSA added little incremental value over simple measure of weight. Conclusion Although statistically significantly related to most outcomes in patients with STEMI including death and shock, body weight provided clinically relevant prognostic information only for the risk of major bleeding and of stroke. Furthermore, BMI or BSA contributed little incremental prognostic information beyond that provided by weight alone. Thus, the existing large body of information concerning the strong prognostic importance of anthropometric measures with outcomes after STEMI should be interpreted in the context of other more important risk factors.

[1]  K. Harjai,et al.  Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions. , 2006, The American journal of cardiology.

[2]  R. Califf,et al.  Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. , 2005, The American journal of cardiology.

[3]  P. Serruys,et al.  Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: The obesity paradox II? , 2005, The American journal of cardiology.

[4]  Lippincott Williams Wilkins,et al.  ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2004 .

[5]  P. Armstrong,et al.  Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). , 2004, The American journal of cardiology.

[6]  P. Armstrong,et al.  Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction , 2003, Circulation.

[7]  H. Gurm,et al.  The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). , 2002, Journal of the American College of Cardiology.

[8]  H. White,et al.  Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial , 2001, The Lancet.

[9]  Y Wang,et al.  Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. , 2000, Stroke.

[10]  K. Lee,et al.  Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. , 2000, Circulation.

[11]  J. Manson,et al.  Annual deaths attributable to obesity in the United States. , 1999, JAMA.

[12]  M. Thun,et al.  Body-mass index and mortality in a prospective cohort of U.S. adults. , 1999, The New England journal of medicine.

[13]  J. Schafer.  Multiple imputation: a primer , 1999, Statistical methods in medical research.

[14]  E. Topol.  A comparison of reteplase with alteplase for acute myocardial infarction. , 1998, The New England journal of medicine.

[15]  Ronald M. Krauss,et al.  American Heart Association Call to Action: Obesity as a Major Risk Factor for Coronary Heart Disease , 1998 .

[16]  M. Evans,et al.  Body weight and mortality among women. , 1997, Canadian family physician Medecin de famille canadien.

[17]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[18]  R. Califf,et al.  Individual risk assessment for intracranial haemorrhage during thrombolytic therapy , 1993, The Lancet.

[19]  J. Manson,et al.  Height and Incidence of Cardiovascular Disease in Male Physicians , 1993, Circulation.

[20]  S. Shapiro,et al.  Stature and the risk of myocardial infarction in women. , 1990, American journal of epidemiology.

[21]  D. Cook,et al.  Short stature, lung function and risk of a heart attack. , 1989, International journal of epidemiology.

[22]  HELEN B. HUBERT,et al.  Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study , 1983, Circulation.

[23]  P. Wolf,et al.  Chronic disease in former college students. I. Early precursors of fatal coronary heart disease. , 1966, American journal of epidemiology.

[24]  E. J. PubMed Citation,et al.  An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction , 2009 .

[25]  Salim Yusuf,et al.  Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. , 2005, American heart journal.

[26]  R. Califf,et al.  Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. , 2000, Journal of the American College of Cardiology.

[27]  G Barbash,et al.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[28]  K. Lee,et al.  Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. , 1997, Circulation.